Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 33Breast Neoplasms 27Carcinoma, Non-Small-Cell Lung 22Triple Negative Breast Neoplasms 19Ovarian Neoplasms 18Lung Neoplasms 18Fallopian Tube Neoplasms 17Neoplasm Metastasis 15Squamous Cell Carcinoma of Head and Neck 12Endometrial Neoplasms 10Neoplasms 9Oropharyngeal Neoplasms 6Mouth Neoplasms 6Esophageal Neoplasms 6Cholangiocarcinoma 6Melanoma 5Colorectal Neoplasms 5Carcinoma 5Adenocarcinoma Of Esophagus 5Stomach Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Carcinoma, Transitional Cell 4Anatomic Stage I Breast Cancer AJCC v8 4Pancreatic Adenocarcinoma 3Inflammatory Breast Neoplasms 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Squamous Cell 3

Interventions

temsirolimus 1ixabepilone 1Vorinostat 1Taxes 1Sirolimus 1Paclitaxel 1Irinotecan 1Erlotinib Hydrochloride 1Epothilones 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adult Solid Neoplasm × Taxes × 1 year × Clear all
NCT01281176 2026-04-20

High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
20 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡